The UK and US have forged a landmark bilateral deal that will guarantee no tariffs on British medicine products being sold in the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has committed to raise expenditure on drugs through the National Health Service (NHS). This pledge secures that duties on these key exports will remain at zero for a period of the next three years.
This deal follows previous statements to significantly raise duties on patented pharmaceutical imports, with increases floated up to 100%.
"This agreement with the UK bolsters the international landscape for innovative medicines and brings long-overdue equity to American-British pharmaceutical trade," a release said.
Trade Importance
Drugs represent one of the Britain's largest goods shipped to the US, which is easily the largest market for major British pharmaceutical firms.
Export figures indicate that in the 12 months to the end of the third quarter, the UK shipped pharmaceutical products worth £11.1bn to the US. This figure made up nearly one-fifth of all goods exports in that timeframe.
"This deal protects work, boosts funding and paves the way for the UK to emerge as a global hub for life sciences," a government official commented.
Specific NHS Changes
The pact entails several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the affordability limit at which it deems new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a aim to double overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to stay within budget will be limited at fifteen percent. Previously, rebates topped twenty percent.
Recent Tensions
The pact follows a ongoing dispute between the sector and the British authorities over spending levels and NHS adoption.
This friction were exacerbated by claims that US customers were charged a premium for the same drugs than consumers in the Britain and the EU.
In recent months, several large drug company projects in the UK have been paused or cancelled, while multi-billion-dollar expansions have been pledged toward US facilities.
One official acknowledged that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had decreased as a share of its resources over the previous ten-year period.
